Potential of anti-inflammatory treatment for cystic fibrosis lung disease

Journal of Inflammation Research

Volumn 3, Issue 1, 2010, Pages 61-74

  Taylor Cousar, Jennifer L ^a   von Kessel, Kelsey A ^a   Young, Robert ^a   Nichols, David P ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

Cystic fibrosis; Inflammation; Survival; Therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; AZITHROMYCIN; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR ANTAGONIST; CORTICOSTEROID; GLUTATHIONE; HYDROXYCHOROQUINE; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; PLACEBO; PREDNISONE; SB 656933; SILDENAFIL; SIMVASTATIN; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADAPTIVE IMMUNITY; ARTICLE; BREATH ANALYSIS; CATARACT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CYSTIC FIBROSIS; DISEASE MODEL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GLUCOSE INTOLERANCE; GROWTH DISORDER; HEMOPTYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LUNG DISEASE; LUNG LAVAGE; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; SIGNAL TRANSDUCTION; SPUTUM ANALYSIS; TH17 CELL; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 77955536419     PISSN: None     EISSN: 11787031     Source Type: Book Series    
DOI: None     Document Type: Article

References (168)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis: state of the art. Am J Respir Crit Care Med. 1996;154:1229-1256.
2. Bedrossian CW, Greenberg SD, Singer DB, et al. The lung in cystic fibrosis. A quantitative study including prevalence or pathologic findings among different age groups. Hum Pathol. 1976;7(2):195-204.
3. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995;151:1075-1082.
4. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995;152:2111-2118.
5. Konstan MW, Hilliard KA, Norvell TM, et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994;150:448-454.
6. Balough K, McCubbin M, Weinberger M, et al. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995;20:63-70.
7. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 1997;156:1197-1204.
8. Muhlebach MS, Stewart PW, Leigh MW, et al. Quantitation of inflammatory response to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med. 1999;160:186-191.
9. Auerbach HS, Williams M, Kirkpatrick JA, et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985;2(8457):686-688.
10. Eigen H, Rosenstein BJ, FitzSimmons S, et al. A multicenter study of alternate- day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr. 1995;126(4):515-523.
11. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;332:848-844.
12. Donati MA, Haver K, Gerson W, et al. Long-term alternate day prednisone therapy in cystic fibrosis. Pediatr Pulmonol. 1990;5:A322.
13. Lands LC, Milner R, Cantin AM, et al. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr. 2007;151:228-230.
14. Konstan MW, Schluchter MD, Xue W, et al. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2007;176:1084-1089.
15. Noah TL, Black HR, Cheng PW, et al. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis. 1997;175:638-647.
16. Perez A, Issler AC, Cotton CU, et al. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol. 2007;292:L383-L395.
17. Dechecchi MC, Nicolis E, Bezzerri V, et al. MPB-07 reduces the inflammatory response to Pseudomonas aeruginosa in cystic fibrosis bronchial cells. Am J Respir Cell Mol Biol. 2007;36: 615-624.
18. van Heeckeren A, Walenga R, Konstan MW, et al. Excessive inflammatory response on cystic fibrosis mice to bronchopulmonary infection with P. aeruginosa. J Clin Invest. 1997;100:2810-2815.
19. McMorran BJ, Palmer JS, Lunn DP, et al. G551D CF mice display an abnormal host response and have impaired clearance of Pseudomonas lung disease. Am J Physiol Lung Cel Mol Physiol. 2001;281:L740-L747.
20. Verhaeghe C, Remouchamps C, Hennuy B, et al. Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem Pharmacol. 2007;73:1982-1994.
21. Li J, Johnson XD, Lazvovskaia S, et al. Signaling intermediates required for NFκB activation and IL-8 expression in CF bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L307-L315.
22. Escotte S, Tabary O, Dusser D, et al. Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-beta kinase pathway. Eur Respir J. 2003;21:574-581.
23. Ribeiro CM, Paradiso AM, Schwab U, et al. Chronic airway infection/ inflammation induces a Ca2+i-dependent hyperinflammatory response in human cystic fibrosis airway epithelia. J Biol Chem. 2005;280:17798-17806.
24. Bonfield TL, Konstan MW, Burfeind P, et al. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol. 1995;13:257-261.
25. Bonfield TL, Konstan MW, Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol. 1999;104(1):72-78.
26. Moore KW, de Waal-Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
27. Osika E, Cavaillon JM, Chadelat K, et al. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur Respir J. 1999;14:339-346.
28. Lentsch AB, Shanley TP, Sarma V, et al. In vivo suppression of NFkB and preservation of IkBalpha by interleukin-10 and interleukin-13. J Clin Invest. 1997;100:2443-2448.
29. Schottelius AJG, Mayo MW, Sartor RB, et al. Interleukin-10 signaling blocks inhibitor of kB kinase activity and nuclear factor kB DNA binding. J Biol Chem. 1999;274:31868-31874.
30. Andersson C, Zaman MM, Jones AB, et al. Alterations in immune respnse and PPAR/LXR regulation in cystic fibrosis macrophages. J Cyst Fibros. 2008;7(1):68-78.
31. Ollero M, Junaidi O, Zaman MM, et al. Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice. J Cell Physiol. 2004;200:235-244.
32. Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated antiinflammatory activity in the cystic fibrosis airway. Nat Immunol. 2004;5:357-358.
33. Starosta V, Ratjen F, Rietschel E, et al. Anti-inflammatory cytokines in cystic fibrosis lung disease. Eur Respir J. 2006;28:581-587.
34. Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease? Inflamm Res. 2007;56:221-227.
35. Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cel Mol Physiol. 2007;292:L519-L523.
36. McAllister F, Henry A, Kreindler JL, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol. 2005;175:404-412.
37. Roussel L, Rousseau S. IL-17 primes airway epithelial cells lacking functional CFTR in increase NOD1 responses. Biochem Biophys Res Commun. 2010;391(1):505-509.
38. Fujisawa T, Velichko S, Thai P, et al. Regulation of airway MUC5AC expression by IL-1beta and IL-17A; the NF-kappaB paradigm. J Immunol. 2009;183(10):6236-6243.
39. Ferretti S, Bonneau O, Dubois GR, et al. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide induced airway neutrophilia: IL-15 as a possible trigger. J Immunol. 2003;170:2106-2112.
40. Chen J, Kinter M, Shank S, et al. Dysfunction of Nrf-2 in CF epithelia leads to excess intracellular H2O2 and inflammatory cytokine production. PLoS ONE. 2008;3:e3367.
41. Li Q, Engelhardt JF. Interleukin-1B induction of NFkB is partially regulated by H2O2-mediated activation of NFkB-inducing kinase. J Biol Chem. 2006;281:1495-1505.
42. Balfour-Lynn IM, Laverty A, Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child. 1996;75:319-322.
43. Grasemann H, Michler E, Wallot M, et al. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol. 1997;24:173-177.
44. Roum JH, Buhl R, McElvaney NG, et al. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol. 1993;75:2419-2424.
45. Gao L, Kim KJ, Yankaskas JR, et al. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol. 1999;277:L113-L118.
46. Nichols DP, Ziady AG, Shank SL, et al. The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cel Mol Physiol. 2009;297(5):L828-L836.
47. Ishii Y, Itoh K, Morishima Y, et al. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol. 2005;175:6968-6975.
48. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol. 2008;180:5662-5669.
49. Jackson PL, Xu X, Wilson L, et al. Human neutrophil elastase-mediated cleavage sites on MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. Mol Med. 2010. Epub 2010 Jan 29.
50. Weldon S, McNally P, McElvaney NG, et al. Decreased levels of secretory leucoprotease inhibitor in the pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degredation. J Immunol. 2009;183:8146-8156.
51. Goyot N, Butler MW, McNally P, et al. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic f ibrosis. J Biol Chem. 2008;283(47):32377-32385.
52. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends, and physician attitudes. Chest. 1999;115:1053-1058.
53. Matthews WJ, Williams M, Oliphint B, et al. Hypogammaglobulinemia in patients with cystic fibrosis. N Engl J Med. 1980;302:245-249.
54. Eigen H, Rosenstein BJ, FitzSimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr. 1995;126(4):515-523.
55. Rosenstein BJ, Eigen H. Risks of alternate day prednisone in patients with cystic fibrosis. Pediatr. 1991;87:245-246.
56. Lai HC, FitzSimmons SC, Allen DB. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med. 2000;342:851-859.
57. Greally P, Hussain MJ, Vergani D, et al. Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child. 1994;71:35-39.
58. Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. 2009;1.
59. Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chroic pulmonary infection. Am Rev Respir Dis. 1990;141:186-192.
60. Scheuren N, Bang H, Munster T, et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol. 1998;123:645-652.
61. Tegeder I, Niederberger E, Israr E, et al. Inhibition of NF-kB and AP-1 activation by R- and S-flurbiprofen. FASEB J. 2001;15:595-597.
62. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749-1756.
63. Florescu DF, Murphy PJ, Kalil AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther. 2009;22(6):467-472.
64. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360:978-984.
65. Verleden GM, Vanaudenaerde BM, Dupont LJ, et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174:566-570.
66. Tsai WC, Rodriguez ML, Young KS, et al. Azithromycin blocks neutrophil recruitment in pseudomonas endobronchial infection. Am J Respir Crit Care Med. 2004;170:1331-1339.
67. Culic O, Erakovic V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450:277-289.
68. Hoffmann N, Lee B, Hentzer M, et al. Azithromycin blocks quorum sensing and alginate polymer formation an dincreases the sensitivity to serum and stationary-growth-phase killing of pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in cftr(-/-) mice. Antimicrob Agents Chemother. 2007;51:3677-3687.
69. Gavilanes X, Huaux F, Meyer M, et al. Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primarycultured epithelial cells from cystic fibrosis mice. J Cyst Fibros. 2009;8(3):203-210.
70. Ribeiro CM, Hurd H, Wu Y, et al. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS ONE. 2009;4(6):e5806.
71. Tramper-Stranders GA, Wolfs TF, Fleer A, et al. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J. 2007;26:8-12.
72. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303:1707-1715.
73. Gruenert DC, Willems M, Cassiman JJ, et al. Established cell lines used in cystic fibrosis research. J Cyst Fibros. 2004;3 Suppl 2:191-196.
74. Doring G, Elborn JS, Johannesson M, et al. Clinical trials in cystic fibrosis. J Cyst Fibros. 2007; 6(2):85-99.
75. DiMango E, Ratner AJ, Bryan R, et al. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest. 1998; 101(11):2598-2605.
76. Kube D, Sontich U, Fletcher D, et al. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol. 2001; 280(3):L493-L502.
77. Kammouni W, Figarella C, Marchand S, et al. Altered cytokine production by cystic fibrosis tracheal gland serous cells. Infect Immun. 1997;65(12):5176-5183.
78. Weber AJ, Soong G, Bryan R, et al. Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Clchannel function. Am J Physiol Lung Cell Mol Physiol. 2001;281(1): L71-L78.
79. Borgatti M, Bezzerri V, Mancini I, et al. Induction of IL-6 gene expression in a CF bronchial epithelial cell line by Pseudomonas aeruginosa is dependent on transcription factors belonging to the Sp1 superfamily. Biochem Biophys Res Commun. 2007;357(4): 977-983.
80. Li J, Johnson XD, Iazvovskaia S, et al. Signaling intermediates required for NF-kappa B activation and IL-8 expression in CF bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;284(2):L307-L315.
81. Banner KH, De Jonge H, Elborn S, et al. Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. J Cyst Fibros. 2009;8(1):1-8.
82. Borthwick DW, West JD, Keighren MA, et al. Murine submucosal glands are clonally derived and show a cystic fibrosis gene-dependent distribution pattern. Am J Respir Cell Mol Biol. 1999;20(6):1181-1189.
83. Pack RJ, Al-Ugaily LH, Morris G, et al. The distribution and structure of cells in the tracheal epithelium of the mouse. Cell Tissue Res. 1980;208(1):65-84.
84. Scholte BJ, Davidson DJ, Wilke M, et al. Animal models of cystic fibrosis. J Cyst Fibros. 2004;3 Suppl 2:183-190.
85. Harris A. Towards an ovine model of cystic fibrosis. Hum Mol Genet. 1997;6(13):2191-2194.
86. Sun X, Yan Z, Yi Y, et al. Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets. J Clin Invest. 2008;118(4):1578-1583.
87. Rogers CS, Stoltz DA, Meyerholz DK, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science. 26 2008;321(5897):1837-1841.
88. Rogers CS, Hao Y, Rokhlina T, et al. Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. J Clin Invest. 2008;118(4):1571-1577.
89. Stoltz DA. Early Pulmonary Findings in a CFTR -/- Pig. North American Cystic Fibrosis Conference. Minneapolis, MN: Wiley-Blackwell; 2009:191.
90. Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med. 2010;2:29ra31.
91. Fibrosis FC. Cystic Fibrosis Foundation National Patient Registry, Annual Data Report, Bethesda, MD; 2007.
92. Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7(5):450-453.
93. McCormick J, Mehta G, Olesen HV, et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet. 20 2010;375(9719):1007-1013.
94. Parker AC, Pritchard P, Preston T, et al. Enhanced drug metabolism in young children with cystic f ibrosis. Arch Dis Child. 1997;77(3):239-241.
95. Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs. 1988;35(5):542-578.
96. Kearns GL. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann Pharmacother. 1993;27(1):74-79.
97. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 28 2002;360(9338):978-984.
98. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57(3):212-216.
99. McPhail GL, Acton JD, Fenchel MC, et al. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr. 2008;153(6):752-757.
100. Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2004;37(5):400-406.
101. Mayer-Hamblett N, Aitken ML, Accurso FJ, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med. 2007;175(8):822-828.
102. Quittner AL, Buu A, Messer MA, et al. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128(4):2347-2354.
103. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc. 2007;4(4):370-377.
104. Hendry J, Elborn JS, Nixon L, et al. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa. Eur Respir J. 1999;14(2):435-438.
105. Koller DY, Gotz M, Wojnarowski C, et al. Relationship between disease severity and inflammatory markers in cystic fibrosis. Arch Dis Child. 1996;75(6):498-501.
106. Norman D, Elborn JS, Cordon SM, et al. Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax. 1991;46(2):91-95.
107. Brown MA, Morgan WJ, Finley PR, et al. Circulating levels of tumor necrosis factor and interleukin-1 in cystic fibrosis. Pediatr Pulmonol. 1991;10(2):86-91.
108. Dorlochter L, Carlsson M, Olafsdottir EJ, et al. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis. J Cyst Fibros. 2004;3(3):179-183.
109. Colombo C, Costantini D, Rocchi A, et al. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol. 2005;40(1):15-21.
110. Roderfeld M, Rath T, Schulz R, et al. Serum matrix metalloproteinases in adult CF patients: relation to pulmonary exacerbation. J Cyst Fibros. 2009;8(5):338-347.
111. Jones AM, Martin L, Bright-Thomas RJ, et al. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa. Eur Respir J. 2003;22(3):503-506.
112. Valletta EA, Rigo A, Bonazzi L, et al. Modif ication of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis. Acta Paediatr. 1992;81(3): 227-230.
113. Downey DG, Martin SL, Dempster M, et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol. 2007;42(3):216-220.
114. Wilmott RW, Frenzke M, Kociela V, et al. Plasma interleukin-1 alpha and beta, tumor necrosis factor-alpha, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis. Pediatr Pulmonol. 1994;18(1):21-27.
115. McColley SA, Stellmach V, Boas SR, et al. Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med. 2000;161(6):1877-1880.
116. Dean TP, Dai Y, Shute JK, et al. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res. 1993;34(2):159-161.
117. Greally P, Hussain MJ, Vergani D, et al. Serum interleukin-1 alpha and soluble interleukin-2 receptor concentrations in cystic fibrosis. Arch Dis Child. 1993;68(6):785-787.
118. Kronborg G, Hansen MB, Svenson M, et al. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol. 1993;15(5):292-297.
119. Eichler I, Nilsson M, Rath R, et al. Human neutrophil lipocalin, a highly specific marker for acute exacerbation in cystic fibrosis. Eur Respir J. 1999;14(5):1145-1149.
120. Downey DG, Brockbank S, Martin SL, et al. Broncoscopy Study Group The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol. 2007;42(8):729-735.
121. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic f ibrosis lung disease. Proc Am Thorac Soc. 2007;4(4):406-417.
122. Wagener JS, Rock MJ, McCubbin MM, et al. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Pulmozyme Pediatric. J Pediatr. 1998;133(4):486-491.
123. Wojtczak HA, Kerby GS, Wagener JS, et al. Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. Pediatr Pulmonol. 2001;32(4):293-302.
124. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J. 2009;33(2):305-311.
125. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol. 2007;42(7):610-623.
126. Ratjen F, Paul K, van Koningsbruggen S, et al. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol. 2005;39(1): 1-4.
127. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med. 2004;169(6):719-725.
128. Ratjen F, Hartog CM, Paul K, et al. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax. 2002;57(11):930-934.
129. Meyer KC, Lewandoski JR, Zimmerman JJ, et al. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy. Am Rev Respir Dis. 1991;144(3 Pt 1):580-585.
130. McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991;337(8738):392-394.
131. McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992;90(4):1296-1301.
132. Carpagnano GE, Barnes PJ, Francis J, et al. Breath condensate pH in children with cystic fibrosis and asthma: a new noninvasive marker of airway inflammation? Chest. 2004;125(6):2005-2010.
133. Karakoc GB, Inal A, Yilmaz M, et al. Exhaled breath condensate MMP-9 levels in children with bronchiectasis. Pediatr Pulmonol. 2009;44(10):1010-1016.
134. Robroeks CM, Rosias PP, van Vliet D, et al. Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children. Pediatr Allergy Immunol. 2008;19(7):652-659.
135. Thomas SR, Kharitonov SA, Scott SF, et al. Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype. Chest. 2000;117(4):1085-1089.
136. Bodini A, D'Orazio C, Peroni D, et al. Biomarkers of neutrophilic inflammation in exhaled air of cystic fibrosis children with bacterial airway infections. Pediatr Pulmonol. 2005;40(6):494-499.
137. Ojoo JC, Mulrennan SA, Kastelik JA, et al. Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis. Thorax. 2005;60(1):22-26.
138. Tate S, MacGregor G, Davis M, et al. Airways in cystic fibrosis are acidified: detection by exhaled breath condensate. Thorax. 2002;57(11):926-929.
139. Newport S, Amin N, Dozor AJ. Exhaled breath condensate pH and ammonia in cystic fibrosis and response to treatment of acute pulmonary exacerbations. Pediatr Pulmonol. 2009;44(9):866-872.
140. Ordonez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med. 15, 2003;168(12):1471-1475.
141. Gilljam H, Malmborg AS, Strandvik B. Conformity of bacterial growth in sputum and contamination free endobronchial samples in patients with cystic fibrosis. Thorax. 1986;41(8):641-646.
142. Aaron SD, Kottachchi D, Ferris WJ, et al. Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur Respir J. 2004;24(4):631-637.
143. Sagel SD, Kapsner R, Osberg I, et al. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med. 15 2001;164(8 Pt 1):1425-1431.
144. Baraldi E, Ghiro L, Piovan V, et al. Safety and success of exhaled breath condensate collection in asthma. Arch Dis Child. 2003;88(4):358-360.
145. de Jong PA, Lindblad A, Rubin L, et al. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax. 2006;61(1):80-85.
146. de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J. 2004;23(1):93-97.
147. Brody AS, Sucharew H, Campbell JD, et al. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. Am J Respir Crit Care Med. 2005;172(9):1128-1132.
148. Nasr SZ, Kuhns LR, Brown RW, et al. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol. 2001;31(5):377-382.
149. Robinson TE, Goris ML, Zhu HJ, et al. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest. 2005;128(4):2327-2335.
150. Nakano Y, Wong JC, de Jong PA, et al. The prediction of small airway dimensions using computed tomography. Am J Respir Crit Care Med. 2005;171(2):142-146.
151. Orlandi I, Moroni C, Camiciottoli G, et al. Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. Radiology. 2005;234(2):604-610.
152. de Jong PA, Nakano Y, Hop WC, et al. Changes in airway dimensions on computed tomography scans of children with cystic fibrosis. Am J Respir Crit Care Med. 2005;172(2):218-224.
153. Niimi A, Matsumoto H, Amitani R, et al. Effect of short-term treatment with inhaled corticosteroid on airway wall thickening in asthma. Am J Med. 2004;116(11):725-731.
154. Puderbach M, Eichinger M, Gahr J, et al. Proton MRI appearance of cystic fibrosis: comparison to CT. Eur Radiol. 2007;17(3): 716-724.
155. Eichinger M, Puderbach M, Fink C, et al. Contrast-enhanced 3D MRI of lung perfusion in children with cystic fibrosis - initial results. Eur Radiol. 2006;16(10):2147-2152.
156. Ley S, Puderbach M, Fink C, et al. Assessment of hemodynamic changes in the systemic and pulmonary arterial circulation in patients with cystic fibrosis using phase-contrast MRI. Eur Radiol. 2005;15(8):1575-1580.
157. Altes TA, Eichinger M, Puderbach M. Magnetic resonance imaging of the lung in cystic f ibrosis. Proc Am Thorac Soc. 2007;4(4):321-327.
158. Mentore K, Froh DK, de Lange EE, et al. Hyperpolarized HHe 3 MRI of the lung in cystic fibrosis: assessment at baseline and after bronchodilator and airway clearance treatment. Acad Radiol. 2005;12(11):1423-1429.
159. Ramsey BW. Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis. Proc Am Thorac Soc. 2007;4(4):359-363.
160. Foundation CF. CFF Drug Development Pipeline. Available from: http://www.cff.org/treatments/Pipeline/. Accessed Apr 5, 2010.
161. Williams B, Robinette M, Slovis B, Deretic V, Perkett E. Hydroxychoroquine: pilot study of anti-inflammatory effects in cystic fibrosis. Pediatr Pulmonol. 2008;(31):A314.
162. Kraynack NC, Xue W, et al. Effect of simvastatin on exhaled nitric oxide and inflammatory markers in sputum in patients with cystic fibrosis. Pediatr Pulmonol. 2008;(31):A300.
163. Konstan MW, Bucur C, et al. Effect of pioglitazone on sputum markers of inflammation in cystic fibrosis. Pediatr Pulmonol. 2008;(31):A310.
164. Ashlock MA, Beall RJ, Hamblett NM, et al. A pipeline of therapies for cystic fibrosis. Semin Respir Crit Care Med. 2009;30(5):611-626.
165. Toward TJ, Smith N, Broadley KJ. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med. 2004;169(2):227-234.
166. Poschet JF, Fazio JA, Timmins GS, et al. Endosomal hyperacidification in cystic fibrosis is due to defective nitric oxide-cylic GMP signalling cascade. EMBO Rep. 2006;7(5):553-559.
167. Poschet JF, Timmins GS, Taylor-Cousar JL, et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L712-L719.
168. Tirouvanziam R, Conrad CK, Bottiglieri T, et al. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A. 2006; 103(12):4628-4633.